Aesthetics Journal: Revance Therapeutics commences botulinum toxin topical gel trial for canthal lines


Biopharmaceutical company Revance Therapeutics has begun a phase 3 study to evaluate the safety and efficacy of a topical drug candidate for the treatment of lateral canthal lines.

Biopharmaceutical company Revance Therapeutics has begun a phase 3 study to evaluate the safety and efficacy of a topical drug candidate for the treatment of lateral canthal lines.

The trial of 450 adult patients will determine the effects of RT001, a topical gel that the company claims could be marketed as the first non-injectable form of botulinum toxin type A, and will use one single application of the treatment and a placebo. Participants will be split into two groups to compare both treatments and assessment will be recorded after 28 days using the Patient Severity Assessment (PSA).

Dan Browne, CEO of Revance said, “We anticipate it will be easier for medical professionals to administer a topical product and that patients will be able to avoid the pain, bruising and downtime which is sometimes associated with needles.”

He continued, “Success in treating canthal lines would set the stage for potential future indications of RT001 topical gel across other areas of the face and body.”

The company plans to release the trial results in the first half of 2016.
Originally published here

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Blog at WordPress.com.

Up ↑

%d bloggers like this: